Practical Answers to Key Clinical Challenges: Optimizing Patient Outcomes in Breast Cancer

CME Program Director: Kathy D. Miller, MD

Faculty:

Kathy S. Albain, MD Hope S. Rugo, MD Linda T. Vahdat, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Explain treatment options for patients with HER2-positive breast cancer
• Discuss the prognosis of patients with node-negative vs node-positive breast cancer
• Identify treatment options for patients with breast cancer who have progressed on trastuzumab and chemotherapy
• Describe the use of adjuvant therapy for HER2-positive metastatic breast cancer
• Summarize outcomes seen with various preoperative regimens for patients with HER2-positive breast cancer

Topics covered include:

• Introduction
• Case 1: A 60-Year-Old Woman With Early-Stage Hormone Receptor–Positive, HER2-Positive Breast Cancer and Negative Nodes
• Case 2: A 53-Year-Old Woman With HER2-Positive Metastatic Breast Cancer After Progressive Disease on Trastuzumab and Chemotherapy
• Case 3: Use of Adjuvant Therapy in a 43-Year-Old Woman With a 2-cm, HER2-Positive Tumor and at Least 3 Positive Nodes
• Case 4: A 42-Year-Old Woman With a 1.5-cm ER-Negative, HER2-Negative Early Breast Cancer and 1 Positive Node
• Case 5: A 59-Year-Old Woman With a 4-cm ER-Positive, HER2-Positive Tumor in Need of Preoperative Therapy
• Case 6: A Patient With a 4-cm ER-Positive, HER2-Negative Tumor in Need of Preoperative Therapy
• Case 7: A 42-Year-Old Woman With ER-Negative, HER2-Negative Metastatic Breast Cancer After FEC
• Case 8: A 46-Year-Old Woman With HER2-Positive Metastatic Breast Cancer After Dose-Dense Doxorubicin/Cyclophosphamide and Paclitaxel